This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
I. INTRODUCTION
The problems encountered in evaluating the effectiveness of treatment methods in multiple sclerosis are well recognized. They result in large part from the nature of the disease, which is characterized by a variable course and many different clinical manifestations. It has been estimated that approximately twothirds of multiple sclerosis patients experience a remission of symptoms at some time during their illness. Many forms of treatment have been proposed with claims of beneficial results for patients at all stages of the disease. Yet, most of these regimens are generally believed to be useless. If the empirical search for an effective treatment for multiple sclerosis is to have any chance of success, it is apparent that a reliable method of accurate assessment must be developed.
In 1960, a symposium concerned with the evaluation of drug therapy in neurological and sensory diseases recognized the many serious difficulties involved in clinical trials of therapy in multiple sclerosis including those pertaining to the conduct of cooperative studies.1 In the months following that symposium, an Ad Hoc committee agreed upon certain diagnostic criteria, scoring systems and principles of design for a suitable protocol for such clinical trials.2 The work of the Ad Hoc committee provided the basis for a subsequently designed protocol for a cooperative study utilizing ACTH vs placebo in the treatment of multiple sclerosis patients in acute exacerbations. A group of neurologists representing ten university treatment centers undertook a cooperative study utilizing this protocol beginning in April 1965. This preliminary report, based on observations of the first 135 cases entered, pre sents the characteristics of the study, demonstrates that adequate randomization of patients can be obtained in this disease and describes means for reasonably accurate evaluation of the many clinical changes seen in multiple sclerosis patients under treatment. Because the study is …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
A PROTOCOL FOR A COOPERATIVE STUDY TO EVALUATE THE THERAPEUTIC EFFECTIVENESS OF ACTH ON MULTIPLE SCLEROSIS IN ACUTE EXACERBATIONS
Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
Management of patients receiving interferon beta-1b for multiple sclerosis